Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers.

Nature communications·2026

Same author

Fatigue after pediatric bone sarcoma: prevalence and associated factors in pediatric and adult patients and survivors after treatment.

Journal of cancer survivorship : research and practice·2026

Same author

International Delphi-based Consensus: Therapeutic Approaches for Pediatric Adrenocortical Carcinoma.

European journal of endocrinology·2026

Same author

Critical appraisal of patient-reported and clinician-reported outcome measures assessing functional outcomes in lower extremity bone sarcoma patients-a COSMIN-based systematic review.

Journal of patient-reported outcomes·2026

Same author

Team Approach: Diagnosis and Management of Pediatric Pelvic Ewing Sarcoma.

JBJS reviews·2026

Same author

Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice-an European Cooperative Study Group for Paediatric Rare Tumours survey.

European journal of endocrinology·2026

Search research articles

Related Experiment Video

Updated: Sep 15, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Prognostic Factors in Newly Diagnosed High-Grade Osteosarcoma-A Systematic Review.

Elisa Tirtei¹, Sascha Wilk Michelsen², Lianne M Haveman³

¹Department of Pediatric Oncology, Regina Margherita Children's Hospital, Turin, Italy.

Cancer Medicine

|July 16, 2025

Summary

This systematic review identified key pretreatment prognostic factors for osteosarcoma, including age, metastasis, tumor size, and site. Further research is needed to validate promising biomarkers like circulating tumor DNA.

Keywords:

newly diagnosed osteosarcoma pretreatment prognostic factors systematic review

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Related Experiment Videos

Last Updated: Sep 15, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Area of Science:

Oncology
Biostatistics
Genetics

Background:

Pretreatment prognostic factors are crucial for osteosarcoma management and clinical trial stratification.
Established factors include metastasis, tumor size, and site; controversial factors include pathological fracture and histologic subtype.
No definitive prognostic tumor biomarker currently exists.

Purpose of the Study:

To systematically review evidence on pretreatment prognostic factors in newly diagnosed osteosarcoma.
To define optimal cut-off values for patient stratification.
To identify potential biomarkers for the FOSTER-CabOS trial.

Main Methods:

Systematic literature search of PubMed, Web-of-science, and Embase (2000-2023).
Inclusion and exclusion criteria applied to 49 selected papers.
Analysis of 14 factors investigated in multiple cohorts or validation studies.

Main Results:

Confirmed prognostic value of patient age, metastasis presence, tumor size, and site (axial vs. appendicular).
Serum alkaline phosphatase and lactate dehydrogenase showed outcome association, but independence is unclear.
Prognostic value of sex, pathological fracture, histologic subtype, and P-glycoprotein expression remains uncertain.

Conclusions:

Age, metastasis, tumor size, and site are confirmed prognostic factors for osteosarcoma.
Circulating tumor DNA and G1/G2 RNA signature show promise as novel biomarkers.
Further validation of these factors and biomarkers is recommended for clinical application.